Related Experiment Videos
DNA screening of hyperlipidemic Afrikaners for familial hypercholesterolemia
M J Kotze1, E Langenhoven, J A Kriek
1Department of Human Genetics, Faculty of Medicine, University of Stellenbosch, Tygerberg, South Africa.
Insights
Founder mutations in the low-density lipoprotein receptor (LDLR) gene are common in Afrikaner familial hypercholesterolemia (FH) patients. Screening hyperlipidemic individuals for these specific LDLR gene mutations aids accurate FH diagnosis.
Area of Science:
- Genetics
- Cardiovascular Disease
- Molecular Biology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder leading to high cholesterol levels.
- Three specific low-density lipoprotein receptor (LDLR) gene mutations account for 90% of FH in Afrikaner patients.
- Accurate diagnosis of FH is crucial for effective patient management and counseling.
Purpose of the Study:
- To determine the prevalence of founder LDLR gene mutations in hyperlipidemic Afrikaner individuals.
- To analyze the distribution of these mutations across different lipid profiles.
- To establish guidelines for screening these mutations in hyperlipidemic populations.
Main Methods:
- Utilized rapid DNA analysis techniques, including restriction enzyme analysis and allele-specific hybridization.
- Analyzed genomic DNA from four groups of Afrikaner individuals.
- Group 1: 84 clinically diagnosed FH patients. Groups 2-4: 89 hyperlipidemic individuals without clinical FH diagnosis.
Main Results:
- Founder-related LDLR gene mutations were identified in 36% of hyperlipidemic individuals not meeting clinical FH criteria.
- This highlights limitations of conventional FH diagnostic methods relying solely on lipid levels and family history.
- The presence of founder mutations offers a definitive diagnostic marker for FH.
Conclusions:
- Conventional FH diagnosis in Afrikaner populations may be insufficient.
- Genetic screening for founder LDLR mutations provides a more accurate FH diagnosis.
- This genetic approach can improve patient counseling and optimize treatment strategies for FH.
Abstract:
Three different point mutations of the low-density lipoprotein receptor (LDLR) gene are responsible for familial hypercholesterolemia (FH) in about 90% of Afrikaner patients. Screening of hyperlipidemic Afrikaner individuals for these founder-related mutations was performed to determine the distribution of the mutations in individuals with different lipid profiles, and to provide guidelines for screening of the mutations in hyperlipidemics. Rapid DNA methods, based on restriction enzyme analysis or allele-specific hybridisation of enzymatically-amplified genomic DNA, have been used to analyse the LDLR gene mutations in four groups of Afrikaner individuals. Group 1 included 84 individuals in whom FH was diagnosed on clinical data. Groups 2-4 included 89 hyperlipidemic individuals who did not fulfil the criteria for inclusion in the FH study group. The founder-related LDLR gene mutations were present in 36% of the hyperlipidemics whose clinical diagnosis excluded them from the FH study group. This indicates that conventional methods for the diagnosis of FH, based mainly on lipid determinations and a family history of coronary heart disease, do not always allow an accurate diagnosis of the disease. Screening of hyperlipidemic Afrikaner individuals for specific founder-related LDLR gene mutations can provide a definite diagnosis of FH, which may lead to better counselling and optimal treatment.